Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
Cancer Commun (Lond)
.
2023 Feb;43(2):171-176.
doi: 10.1002/cac2.12400.
Epub 2023 Jan 22.
Authors
Limin Zou
1
,
Yueli Qi
1
,
Yongling Jiang
2
,
Ling Tang
1
,
Yu Du
1
,
Boyuan Zhao
1
,
Yanzhe Sun
1
,
Meiyi Xiang
1
,
Jun Ma
3
,
Zhimin Yang
1
Affiliations
1
Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
2
Office of Management and Communication, Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, P. R. China.
3
Harbin Institute of Hematology and Oncology, Harbin 150010, Heilongjiang, P. R. China.
PMID:
36683350
PMCID:
PMC9926957
DOI:
10.1002/cac2.12400
No abstract available
Publication types
Editorial
MeSH terms
Antineoplastic Agents* / therapeutic use
China
Humans
Substances
Antineoplastic Agents